Tritace 2.5mg Tablets

  • Name:

    Tritace 2.5mg Tablets

  • Company:
    info
  • Active Ingredients:

    Ramipril

  • Legal Category:

    Product subject to medical prescription which may be renewed (B)

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 06/07/20

files-icon(Click to Download)
Summary of Product Characteristics last updated on medicines.ie: 11/9/2019

Click on this link to Download PDF directly

SANOFI

SANOFI

Company Products

Medicine NameActive Ingredients
Medicine Name Adenocor Active Ingredients Adenosine
Medicine Name Amaryl 1mg Tablets Active Ingredients Glimepiride
Medicine Name Amaryl 3mg Tablets Active Ingredients Glimepiride
Medicine Name Anthisan Cream Active Ingredients Mepyramine Maleate
Medicine Name Apidra 100 units/ml solution for injection in a cartridge Active Ingredients Insulin Glulisine
Medicine Name Apidra 100 Units/ml solution for injection in a vial Active Ingredients Insulin Glulisine
Medicine Name Apidra SoloStar 100 units/ml solution for injection in a pre-filled pen Active Ingredients Insulin Glulisine
Medicine Name Aprovel 150mg film-coated tablets Active Ingredients Irbesartan
Medicine Name Aprovel 300mg film-coated tablets Active Ingredients Irbesartan
Medicine Name Aprovel 75mg film-coated tablets Active Ingredients Irbesartan
Medicine Name Arava 10 mg film-coated tablets Active Ingredients Leflunomide
Medicine Name Arava 20 mg film-coated tablets Active Ingredients Leflunomide
Medicine Name Bisolvon Oral Solution Active Ingredients Bromhexine hydrochloride
Medicine Name Brolene 0.1%w/v Eye Drops Solution Active Ingredients Propamidine Isethionate
Medicine Name Brolene 0.15% w/w Eye Ointment Active Ingredients Dibromopropamidine Isethionate
Medicine Name Buscopan 10 mg Coated Tablets Active Ingredients hyoscine butylbromide
Medicine Name Buscopan Ampoules Active Ingredients hyoscine butylbromide
Medicine Name Buscopan Rx 10mg Coated Tablets Active Ingredients hyoscine butylbromide
Medicine Name Calcium Resonium Active Ingredients Calcium polystyrene sulfonate
Medicine Name Cerubidin 20mg Powder for Solution for Injection Active Ingredients daunorubicin hydrochloride
Medicine Name Cidomycin Paediatric 20mg/2ml Solution For Injection Active Ingredients Gentamicin sulfate
Medicine Name Claforan Powder for Solution for Injection 1g Active Ingredients Cefotaxime sodium
Medicine Name Claforan Powder for Solution for Injection 500mg Active Ingredients Cefotaxime sodium
Medicine Name Clexane 10,000 IU (100mg)/1ml Solution for Injection Active Ingredients Enoxaparin sodium
Medicine Name Clexane 2,000 IU (20 mg) /0.2 mL Solution for Injection Active Ingredients Enoxaparin sodium
1 - 0 of 176 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 6 July 2020 PIL

Reasons for updating

  • XPIL Removed

Updated on 5 March 2020 PIL

Reasons for updating

  • Removal of one or more presentations from joint PIL

Free text change information supplied by the pharmaceutical company

Section 6 of the PIL has been updated: To delete the 1.25mg strength of Tritace (ramipril) in Italy only.

Updated on 11 September 2019 SmPC

Reasons for updating

  • New SmPC for medicines.ie

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 11 September 2019 SmPC

Reasons for updating

  • New SmPC for medicines.ie

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 11 September 2019 PIL

Reasons for updating

  • New PIL for medicines.ie

Updated on 6 April 2018 SmPC

Reasons for updating

  • New SmPC for new product

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 6 April 2018 SmPC

Reasons for updating

  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Section 4.3 Contraindications  added:-

·         Concomitant use with sacubitril/valsartan therapy (see sections 4.4 and 4.5).

Section 4.4 Special Warnings and Precautions in Use added:-

Under sub heading  Angioedema wording added:-

·         Of angioedema

·          which may cause angioedema

·         Neprilysin (NEP) inhibitors (such as)The combination of ramipril with sacubitril/valsartan is contraindicated due to the increased risk of angioedema (see sections 4.3 and 4.5).

Section 4.5 Interaction with other medicinal products and other forms of interaction added:-

·         The concomitant use of ACE inhibitors with sacubitril/valsartan is contraindicated as this increases the risk of angioedema (see sections 4.3 and 4.4). Treatment with ramipril must not be started until 36 hours after taking the last dose of sacubitril/valsartan.

Sacubitril/valsartan must not be started until 36 hours after the last dose of Tritace.

 

Under sub heading Precautions for use added:-

·         Neprilysin (NEP) inhibitors replaces Racecadotril

·         Word potential removed and minor typographical changes to paragraph.

New sub heading added:-

·         Sacubitril/valsartan        

·         The concomitant use of ACE inhibitors with sacubitril/valsartan is contraindicated as this increases the risk of angioedema.

Updated on 4 April 2018 PIL

Reasons for updating

  • New PIL for new product

Updated on 4 April 2018 PIL

Reasons for updating

  • Change to section 2 - what you need to know - contraindications
  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 6 - date of revision
  • Change to other sources of information section

Updated on 31 May 2017 PIL

Reasons for updating

  • Change to section 6 - what the product contains
  • Change to section 6 - what the product looks like and pack contents
  • Change to section 6 - marketing authorisation holder
  • Change to section 6 - marketing authorisation number
  • Change to section 6 - manufacturer
  • Change to section 6 - date of revision

Updated on 31 May 2017 PIL

Reasons for updating

  • New PIL for new product

Updated on 19 January 2017 PIL

Reasons for updating

  • Change to section 2 - what you need to know - contraindications
  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 2 - use in children and adolescents
  • Change to section 2 - interactions with other medicines, food or drink
  • Change to section 2 - pregnancy, breast feeding and fertility
  • Change to section 2 - driving and using machines
  • Change to section 2 - excipient warnings
  • Change to section 4 - possible side effects
  • Change to section 4 - how to report a side effect

Updated on 19 January 2017 SmPC

Reasons for updating

  • Correction of spelling/typing errors

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Email address for HPRA in the SPCs was stated as @hpra.i.e rather than hpra.ie. This has now been amended.

Updated on 19 January 2017 SmPC

Reasons for updating

  • New SmPC for new product

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 19 December 2016 SmPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 3 - Pharmaceutical form
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.9 - Overdose
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Renewal

Updated on 18 November 2016 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

The Summary of Product Characteristics (SmPC) is updated with information concerning the interaction of ramipril with racecadotrilin sections 4.4 “Special Warnings and Precautions for use” and 4.5 “Interaction with other medicinal products

The package leaflet (PL) is impacted by these changes in section 2.

Updated on 17 November 2016 PIL

Reasons for updating

  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 2 - interactions with other medicines, food or drink
  • Change to section 6 - date of revision

Updated on 1 September 2015 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.8 - Undesirable effects
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 4.9 - Overdose
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 6.6 - Special precautions for disposal and other handling
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Section 4.2, 4.3, 4.6, 4.9, 5.1, 5.2 & 6.6 have had minor updates such as changes to headings and section references.

Section 4.4 'Angioedema' paragraph has been updated to include information on increased risk in patients of mTOR inhibitors.
Section 4.5 New paragraph included at the end regarding mTOR inhibitors.
Section 4.8 Table has been updated with the following sections moved in relation to their seriousness:
- Immune system disorders
- Endocrine disorders
- Metabolism and nutrition disorders
- Psychiatric disorders
- Cardiac disorders
- Vascular disorders
- Hepatobiliary disorders
- Renal and urinary disorders
- Reproductive system and breast disorders
New paragraph on the reporting of suspected adverse reactions included.

Updated on 20 August 2015 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to side-effects
  • Change to drug interactions
  • Change to date of revision

Updated on 18 March 2015 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Section 4.2 updated to include reference to other sections.
Section 4.3 updated info on the concomitant use of Tritace with aliskiren containing products.
Section 4.4 updated regarding use with AIIRAs (angiotensin II receptor antagonists) and new paragraph 'Dual blockade of the renin-angiotensin-aldosterone system (RAAS)'.
Section 4.5 updated to include use with aliskiren and RAAS.
Section 4.6 'The use of ACE inhibitors' changed to 'Tritace'. AIIRA included and 'oliguria and hyperkalaemia' included.
Section 5.1 new section on 'Dual blockade of the renin-angiotensin-aldosterone system (RAAS).
Section 5.2 minor changes.

Updated on 16 March 2015 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to drug interactions
  • Change to information about pregnancy or lactation
  • Change to date of revision

Updated on 26 November 2014 SmPC

Reasons for updating

  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text
  • Change to section 6.5 - Nature and contents of container

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Section 4.3: updated to include a new contraindication regarding aliskiren containing medicinal products in patients with diabetes or renal impairment.
Section 4.4: Special populations updated to include information regarding aliskiren containing medicinal products.
Hyperkalaemia has been updated to Electrolyte Monitoring: Hyperkalaemia - additional information that Syndrome of Inappropriate Anti-diruetic Hormone (SIADH) and subsequent hyponatremia has been observed in some patients treated with ramipril and the medical conditions that may increase the risk.
Section 4.5: updated to include a information regarding the contraindication of aliskiren containing medicinal products.
Section 4.8: Endocrine disorders included.
Section 6.5: 'Not all pack sizes may be marketed.' included.

Updated on 21 November 2014 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change of contraindications
  • Change to drug interactions
  • Change to further information section

Updated on 7 November 2014 SmPC

Reasons for updating

  • Change to section 6.5 - Nature and contents of container

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Type IAIN - B.II.e.5 Change in pack size of the finished product –a) Change in the number of units (e.g. tablets, ampoules, etc.) in a pack – 1. Change within the range of the currently approved pack sizes

Updated on 28 April 2014 SmPC

Reasons for updating

  • Change to section 6.3 - Shelf life

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Type IAIN – B.II.f.1.a.1 Change in the shelf-life or storage conditions of the finished product - Reduction of the shelf life of the finished product - As packaged for sale.

years


Updated on 16 April 2013 SmPC

Reasons for updating

  • Change to section 7 - Marketing authorisation holder

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Type IAIN group bulk, category A.1, application to change the name of the Marketing Authorisation Holder (MAH) in UK, Ireland and Portugal, as well as the MAH address in the UK.

Updated on 4 January 2013 PIL

Reasons for updating

  • Change to product name

Updated on 23 August 2012 SmPC

Reasons for updating

  • New individual SPC (was previously included in combined SPC)

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

None provided

Updated on 23 August 2012 PIL

Reasons for updating

  • Improved electronic presentation

Updated on 17 August 2012 PIL

Reasons for updating

  • Improved electronic presentation

Updated on 2 February 2011 PIL

Reasons for updating

  • Change due to user-testing of patient information

Updated on 23 August 2007 PIL

Reasons for updating

  • Change to marketing authorisation holder

Updated on 19 December 2006 PIL

Reasons for updating

  • Improved electronic presentation

Updated on 19 August 2004 PIL

Reasons for updating

  • New PIL for medicines.ie